Skip Nav Destination
Issues
1 June 2014
-
Cover Image
Cover Image
The cover shows a section of a lymph node biopsy from a patient with follicular lymphoma. Multicolor immunohistochemical staining with magnified inserts show co-localization of CD3 (yellow) and PD1 (blue). For details, see the article by Smeltzer and colleagues on page 2862 of this issue. - PDF Icon PDF LinkTable of Contents
ISSN 1078-0432
EISSN 1557-3265
Highlights
CCR Translations
Statistics in Clinical Cancer Research
Molecular Pathways
Perspectives
Human Cancer Biology
Author Choice
CADM1 Expression and Stepwise Downregulation of CD7 Are Closely Associated with Clonal Expansion of HTLV-I–Infected Cells in Adult T-cell Leukemia/Lymphoma
Seiichiro Kobayashi; Kazumi Nakano; Eri Watanabe; Tomohiro Ishigaki; Nobuhiro Ohno; Koichiro Yuji; Naoki Oyaizu; Satomi Asanuma; Makoto Yamagishi; Tadanori Yamochi; Nobukazu Watanabe; Arinobu Tojo; Toshiki Watanabe; Kaoru Uchimaru
Pattern of CD14+ Follicular Dendritic Cells and PD1+ T Cells Independently Predicts Time to Transformation in Follicular Lymphoma
Jacob P. Smeltzer; Jason M. Jones; Steven C. Ziesmer; Deanna M. Grote; Bing Xiu; Kay M. Ristow; Zhi Zhang Yang; Grzegorz S. Nowakowski; Andrew L. Feldman; James R. Cerhan; Anne J. Novak; Stephen M. Ansell
A Surprising Cross-Species Conservation in the Genomic Landscape of Mouse and Human Oral Cancer Identifies a Transcriptional Signature Predicting Metastatic Disease
Michael D. Onken; Ashley E. Winkler; Krishna-Latha Kanchi; Varun Chalivendra; Jonathan H. Law; Charles G. Rickert; Dorina Kallogjeri; Nancy P. Judd; Gavin P. Dunn; Jay F. Piccirillo; James S. Lewis, Jr; Elaine R. Mardis; Ravindra Uppaluri
Targetable Signaling Pathway Mutations Are Associated with Malignant Phenotype in IDH-Mutant Gliomas
Hiroaki Wakimoto; Shota Tanaka; William T. Curry; Franziska Loebel; Dan Zhao; Kensuke Tateishi; Juxiang Chen; Lindsay K. Klofas; Nina Lelic; James C. Kim; Dora Dias-Santagata; Leif W. Ellisen; Darrell R. Borger; Sarah-Maria Fendt; Matthew G. Vander Heiden; Tracy T. Batchelor; A. John Iafrate; Daniel P. Cahill; Andrew S. Chi
Cancer Therapy: Preclinical
Chimeric Rat/Human HER2 Efficiently Circumvents HER2 Tolerance in Cancer Patients
Sergio Occhipinti; Laura Sponton; Simona Rolla; Cristiana Caorsi; Anna Novarino; Michela Donadio; Sara Bustreo; Maria Antonietta Satolli; Carla Pecchioni; Cristina Marchini; Augusto Amici; Federica Cavallo; Paola Cappello; Daniele Pierobon; Francesco Novelli; Mirella Giovarelli
Ganitumab (AMG 479) Inhibits IGF-II–Dependent Ovarian Cancer Growth and Potentiates Platinum-Based Chemotherapy
Pedro J. Beltran; Frank J. Calzone; Petia Mitchell; Young-Ah Chung; Elaina Cajulis; Gordon Moody; Brian Belmontes; Chi-Ming Li; Steven Vonderfecht; Victor E. Velculescu; Guorong Yang; Jingwei Qi; Dennis J. Slamon; Gottfried E. Konecny
Imaging, Diagnosis, Prognosis
Evaluation of Diffusion-Weighted MRI for Pretherapeutic Assessment and Staging of Lymphoma: Results of a Prospective Study in 140 Patients
Marius E. Mayerhoefer; Georgios Karanikas; Kurt Kletter; Helmut Prosch; Barbara Kiesewetter; Cathrin Skrabs; Edit Porpaczy; Michael Weber; Katja Pinker-Domenig; Dominik Berzaczy; Martha Hoffmann; Christian Sillaber; Ulrich Jaeger; Leonhard Müllauer; Ingrid Simonitsch-Klupp; Werner Dolak; Alexander Gaiger; Philipp Ubl; Julius Lukas; Markus Raderer
Cancer Therapy: Clinical
Clinical Activity of Adjuvant Cytokine-Induced Killer Cell Immunotherapy in Patients with Post-Mastectomy Triple-Negative Breast Cancer
Ke Pan; Xun-Xing Guan; Yong-Qiang Li; Jing-Jing Zhao; Jian-Jun Li; Hui-Juan Qiu; De-Sheng Weng; Qi-Jing Wang; Qing Liu; Li-Xi Huang; Jia He; Shi-Ping Chen; Miao-La Ke; Yi-Xin Zeng; Jian-Chuan Xia
Predictive Biomarkers and Personalized Medicine
Prognostic Biomarkers in Phase II Trial of Cetuximab-Containing Induction and Chemoradiation in Resectable HNSCC: Eastern Cooperative Oncology Group E2303
Amanda Psyrri; Ju-Whei Lee; Eirini Pectasides; Maria Vassilakopoulou; Efstratios K. Kosmidis; Barbara A. Burtness; David L. Rimm; Harold J. Wanebo; Arlene A. Forastiere
KRAS Codon 12 and 13 Mutations in Relation to Disease-Free Survival in BRAF–Wild-Type Stage III Colon Cancers from an Adjuvant Chemotherapy Trial (N0147 Alliance)
Harry H. Yoon; David Tougeron; Qian Shi; Steven R. Alberts; Michelle R. Mahoney; Garth D. Nelson; Suresh G. Nair; Stephen N. Thibodeau; Richard M. Goldberg; Daniel J. Sargent; Frank A. Sinicrope; for the Alliance for Clinical Trials in Oncology
Correction
Advertisement
NOTICE: This notice serves to inform the reader that, in 2023, AACR received a donation by Pfizer of the rights to royalties from the sale—within the United States—of Bavencio® (avelumab), a pharmaceutical owned by Merck. None of these funds are being, or will be, used to directly support any specific publication or author. If an individual article is published that deals with this particular drug, such article will include standard financial disclosures per AACR journal policy. For more detail regarding AACR’s established policies for authors, please go to https://aacrjournals.org/pages/editorial-policies#coi.
RSS Feeds